Multi-omics service company Panome Bio launched its global phosphoproteomics platform, which has been created to analyze both protein abundance and protein phosphorylation events, a key regulatory mechanism in virtually all biological processes.
The company’s phosphoproteomics capabilities provide understanding of the disrupted signaling pathways that drive various diseases and enable the identification of novel drug targets, elucidation of the mechanisms of drug resistance, and pinpointing indicators of treatment response and patient subgroups, according to Gary Patti, PhD, CSO at Panome Bio.
“Phosphorylation is a key mechanism for regulating protein activity and signaling pathways,” he says. “Altered phosphorylation patterns are often associated with diseases. Unlike affinity-based methods using aptamers and antibodies to survey the proteome, mass spectrometry-based proteomics is able to measure phosphorylation at a global level across thousands of proteins.
“Large-scale analysis of both protein levels and post-translational modifications such as phosphorylation will provide unprecedented insight into human health.”
The Panome Bio platform leverages LC/MS techniques and advanced computational processing algorithms. This reported technology enables the routine detection of 15,000 phosphosites and 7,000 unique proteins per sample. The data is then translated into actionable insights through proprietary pathway analysis, network mapping, and kinase activity assessments.
The post Panome Bio Adds Global Phosphoproteomics to its Portfolio of Multi-Omic Discovery Solutions appeared first on GEN - Genetic Engineering and Biotechnology News.
The company’s phosphoproteomics capabilities provide understanding of the disrupted signaling pathways that drive various diseases and enable the identification of novel drug targets, elucidation of the mechanisms of drug resistance, and pinpointing indicators of treatment response and patient subgroups, according to Gary Patti, PhD, CSO at Panome Bio.
“Phosphorylation is a key mechanism for regulating protein activity and signaling pathways,” he says. “Altered phosphorylation patterns are often associated with diseases. Unlike affinity-based methods using aptamers and antibodies to survey the proteome, mass spectrometry-based proteomics is able to measure phosphorylation at a global level across thousands of proteins.
“Large-scale analysis of both protein levels and post-translational modifications such as phosphorylation will provide unprecedented insight into human health.”
The Panome Bio platform leverages LC/MS techniques and advanced computational processing algorithms. This reported technology enables the routine detection of 15,000 phosphosites and 7,000 unique proteins per sample. The data is then translated into actionable insights through proprietary pathway analysis, network mapping, and kinase activity assessments.
The post Panome Bio Adds Global Phosphoproteomics to its Portfolio of Multi-Omic Discovery Solutions appeared first on GEN - Genetic Engineering and Biotechnology News.